Peritonealdialyse bei Diabetikern

Die Peritonealdialyse hat sich in den letzten Jahren zu einem der Hämodialyse ebenbürtigen, für bestimmte Patientengruppen möglicherweise sogar überlegenen Verfahren der Nierenersatztherapie etabliert. Bei etwa einem Drittel der Patienten, die dialysepflichtig werden, ist der Diabetes als Ursache der Nierenerkrankung anzusehen [15]. Der Anteil der Diabetiker ist in der Altersklasse der 60 - 79-Jährigen am höchsten [7]. Insgesamt gewinnt der Diabetes mellitus immer mehr an Bedeutung.

Literatur

• 1 Artik S. Infektiöse Katheter-Komplikationen und Peritonitiden unter kontinuierlicher ambulanter Peritonealdialyse,. Dissertation an der Heinrich-Heine-Universität 1999
• 2 Attman P O, Samuelsson O, Johansson A C, Moberly J B, Alaupovic P. Dialysis modalities and dyslipidemia.  Kidney Int. 2003;  84 110-112 (Suppl)
• 3 Budde K, Neumayer H H, Fritsche L, Su/ow/cz V X, Stompor T, Eckland D. The pharmacokinetics of pioglitazone in patients with Impaired renal function.  Br J Clin Pharmacol. 2003;  55 368-374
• 4 Czock D, Aisenpreis U, Rasche F M, Jehle P M. Pharmacokinetics and pharmacodynamics of lispro-insulin in hemodialysis patients with diabetes mellitus.  Int J Clin Pharmacol Ther. 2003;  41 492-497
• 5 Davies S J, Phillips L, Naish P F, Russell G I. Quantifying comorbidity in peritoneal dialysis patients and its relationship to other predictors of survival.  Nephrol Dial Transplant. 2002;  17 1085-1092
• 6 Fenton S SA, Schaubel D E, Desmeules M. et al . Hemodialysis versus peritoneal dialysis: a comparison of adjusted mortality rates.  Am J Kidney Dis. 1997;  30 334-342
• 7 Frei U, Schober-Halstenberg H -J. Nierenersatztherapie in Deutschland. Jahresberichte der Quasi Niere 2003/2004
• 8 Friedlander M A, Hricik D E. Optimizing end-stage renal disease therapy for the patient with diabetes mellitus.  Semin Nephrol. 1997;  17 331-345
• 9 Heaf J G, Lokkegaard H, Madsen M. Initial survival advantage of peritoneal dialysis relative to hemodialysis.  Nephrol Dial Transplant. 2002;  17 112-117
• 10 Hundal R S, Inzucchi S E. Metformin: new understandings, new uses.  Drugs. 2003;  63 1879-1894
• 11 Garrat H N, Brady P A, Hassinger N L, Grill D E, Terzic A, Holmes D R. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction.  J Am Coll Cardiol. 1999;  33 119-124
• 12 Lin S H, Lin Y F, Kuo S W, Hsu Y J, Hung Y J. Rosiglitazone improves glucose metabolism in nondiabetic uremic patients on CAPD.  Am J Kidney Dis. 2003;  42 774-780
• 13 Lindholm B, Norbeck H E. Serum lipids and lipoproteins during continuous ambulatory peritoneal dialysis.  Acta Med Scand. 1986;  220 143-151
• 14 Marbury T C, Ruckle J L, Hatorp V, Andersen M P, Nielsen K K, Huang W C, Strange R. Pharmacokinetics of repaglinide in subjects with renal impairment.  Clin Pharmacol Ther. 2000;  67 7-15
• 15 Markell M S, Friedmann E A. Care of the diabetic patients with end stage renal disease.  Semin Nephrol. 1990;  10 274-286
• 16 Marshall J, Jennings P, Scott A, Fluck R J, McIntyre C W. Glycemic control in diabetic CAPD patients assessed by continuous glucose monitoring system (CGMS).  Kidney Int. 2003;  64 1480-1486
• 17 Miguel A, García-Ramón R, Pérez-Contreras J, Gómez-Roldán C, Alvariño J. et al . Comorbidity and Mortality in Peritoneal Dialysis: A Comparative Study of Type 1 and 2 Diabetes versus Nondiabetic Patients.  Nephron. 2002;  90 290-296
• 18 Nakayama M, Yokoyama K, Kubo H, Matsumoto H, Hasegawa T, Shigematsu T, Kawaguchi Y, Sakai O. The effect of ultra-low sodium dialysate in CAPD: A kinetic and clinical analysis.  Clin Nephrol. 1996;  45 188-193
• 19 National Kidney Foundation Dialysis Outcomes Quality Initiative . NKF-DOQI clinical practise guidelines: Update 2000.  Am J Kidney Dis. 2001;  37 65-136 (Suppl 1)
• 20 Nevalainen P, Lahtela J T, Mustonen J, Pasternack A. The influence of peritoneal dialysis and the use of subcutaneous and intraperitoneal insulin on glucose metabolism and serum lipids in type 1 diabetic patients.  Nephrol Dial Transplant. 1997;  12 145-150
• 21 Nolph K D, Cutler S J, Steinberg S M, Novak J W. Special studies from the NIH USA CAPD Registry.  Perit Dial Bull. 1986;  6 28-35
• 22 Paniagua R, Amato D, Vonesh E, Correa-Rotter R, Ramos A, Moran J, Mujais S. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX: a prospective, randomized, controlled trial.  J Am Soc Nephrol. 2002;  13 1307-1320
• 23 Plum J, Erren C, Fieseler C, Kirchgessner J, Passlick-Deetjen J, Grabensee B. An amino acid based peritoneal dialysis fluid buffered with bicarbonate versus glucose/bicarbonate and glucose/lactate solutions: an intra-individual randomised study.  Peritoneal Dialysis International. 1999;  19 418-428
• 24 Ruotolo G, Micossi P, Galimberti G. et al . Effects of intraperitoneal versus subcutaneous insulin administration on lipoprotein metabolism in Type I diabetes.  Metabolism. 1990;  38 598
• 25 Tanna M M, Vonesh E F, Korbet S M. Patient survival among incident peritoneal dialysis and hemodialysis patients in an urban setting.  Am J Kidney Dis. 2000;  36 1175-1182
• 26 Vanholder R, Heering P, Loo A V, Biesen W V, Lambert M C, Hesse U, Vennet M V, Grabensee B, Lameire N. Reduced incidence of acute renal graft failure in patients treated with peritoneal dialysis compared with hemodialysis.  Am J Kidney Dis. 1999;  33 934
• 27 Viglino G, Cancarini G C, Catizone L, Cocchi R, De Vecchi A, Lupo A, Salomone M, Segoloni G P, Giangrande A. Ten years experience of CAPD in diabetics: comparison of results with non-diabetics. Italian Cooperative Peritoneal Dialysis Study Group.  Nephrol Dial Transplant. 1994;  9 1443-1448